(Simon et al., 2009) It is also limited to higher incidence biomarker subgroups (KRAS mutation ∼40% of colorectal cancers) such that there is adequate statistical power to identify a differential benefit based on the biomarker. Here, KRAS is linked to colorectal cancer.